RYAAY

63.75

+2.71%↑

KNEBV.FI

53.68

+0.83%↑

MTX1

378.8

+0.88%↑

WRT1V.FI

24.22

+0.37%↑

BVI

26.86

+1.13%↑

RYAAY

63.75

+2.71%↑

KNEBV.FI

53.68

+0.83%↑

MTX1

378.8

+0.88%↑

WRT1V.FI

24.22

+0.37%↑

BVI

26.86

+1.13%↑

RYAAY

63.75

+2.71%↑

KNEBV.FI

53.68

+0.83%↑

MTX1

378.8

+0.88%↑

WRT1V.FI

24.22

+0.37%↑

BVI

26.86

+1.13%↑

RYAAY

63.75

+2.71%↑

KNEBV.FI

53.68

+0.83%↑

MTX1

378.8

+0.88%↑

WRT1V.FI

24.22

+0.37%↑

BVI

26.86

+1.13%↑

RYAAY

63.75

+2.71%↑

KNEBV.FI

53.68

+0.83%↑

MTX1

378.8

+0.88%↑

WRT1V.FI

24.22

+0.37%↑

BVI

26.86

+1.13%↑

Search

mutares AG

Open

26.45 -5.2

Overview

Share price change

24h

Current

Min

26.55

Max

28.1

Key metrics

By Trading Economics

Income

-250M

Sales

2.7B

Dividend yield

6.47

Profit margin

-9.33

Employees

29,000

EBITDA

-212M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+62.07% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

6.47%

2.27%

Next Earnings

12 Aug 2025

Market Stats

By TradingEconomics

Market Cap

690M

Previous open

31.65

Previous close

26.45

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

mutares AG Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 21:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 Aug 2025, 21:21 UTC

Earnings
Major Market Movers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 Aug 2025, 20:45 UTC

Earnings

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 Aug 2025, 19:15 UTC

Major Market Movers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 Aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 Aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 Aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 Aug 2025, 21:30 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 21:21 UTC

Earnings
Acquisitions, Mergers, Takeovers

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 Aug 2025, 21:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 Aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss $938M >RIG

4 Aug 2025, 20:25 UTC

Earnings

Transocean 2Q Loss/Shr $1.06 >RIG

4 Aug 2025, 20:18 UTC

Earnings

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 Aug 2025, 20:15 UTC

Earnings

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 Aug 2025, 20:14 UTC

Earnings

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 Aug 2025, 20:13 UTC

Earnings

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 Aug 2025, 20:09 UTC

Earnings

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 Aug 2025, 20:06 UTC

Earnings

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 Aug 2025, 20:01 UTC

Earnings

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 Aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 Aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 Aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 Aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Comparison

Price change

mutares AG Forecast

Price Target

By TipRanks

62.07% upside

12 Months Forecast

Average 47 EUR  62.07%

High 47 EUR

Low 47 EUR

Based on 1 Wall Street analysts offering 12 month price targets formutares AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

32.95 / 35.05Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About mutares AG

Mutares SE & Co. KGaA is a private equity firm specializing in investments in secondary direct, special situations, bridge financing, recapitalization, distressed/vulture, management succession, reorganization, carve-outs, turnarounds, spin-offs and re-funding. It also considers co-investments. The firm typically acquires small and medium-sized companies. It also focuses on platform and add-on acquisitions. The firm makes investments in automotive and mobility, wood and paper, construction and infrastructure, engineering, consumer goods and services, technology, commercial repair services, automobiles and components, retail and food, healthcare equipment and services, and materials including containers and packaging. The firm primarily invests in companies with established market positions and whose focus of activity is on Europe, North America and Asia. It considers acquiring companies that have revenues between "100 million ($107.33 million) and "750 million ($804.94 million) with an EBITDA up to "5 million ($5.37 million). It prefers to acquire a controlling and majority stake in its portfolio companies. It typically makes long term investments with a holding period between three and five years. The firm prefers to invest from its personal capital and from balance sheet investments. Mutares SE & Co. KGaA was founded in February 2008 and is based in Munich, Germany, with additional offices in across Europe and Asia.